← Leaderboards
Robert S. Dipaola
Univ Of Med/Dent Nj-R W Johnson Med Sch
$4,788,194
Attributed
$7,968,449
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2008–19$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$34,797,564 · 5
By mechanism
P30$26,829,115 · 1
UM1$6,010,522 · 2
U01$1,607,939 · 1
R01$349,988 · 1
Top collaborators
- William E. Carson2 shared
- Michael R Grever2 shared
- Glenn Liu2 shared
- Zhuo Zhang1 shared
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Peter S Amenta$120,403
- Suzie Chen$3,617,728
- Panos Georgopoulos$3,328,722
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResearch PersonnelMalignant NeoplasmsPharmacy FacilityMonitorCancer Institute Of New JerseyNew JerseyResource SharingServicesTraining And EducationBiometryClinical TrialsComprehensive Cancer CenterProgramsLaboratoriesProtocols DocumentationDrug KineticsPharmacodynamicsUniversitiesSafetyBaseEvaluationGrantMedicine
Grant awards (47)
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$1,541,209
UM1 · FY2019 · CA
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$1,512,192
UM1 · FY2018 · CA
Targeting p62 as a more optimal approach to inhibit autophagy using verteporfin as a repurposed therapeutic in prostate cancer$349,988
R01 · FY2018 · CA
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$300,000
UM1 · FY2017 · CA
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$957,122
UM1 · FY2016 · CA
Cancer Center Support Grant$2,922,756
P30 · FY2015 · CA · contact PI
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$850,000
UM1 · FY2015 · CA · contact PI
Cancer Center Support Grant$253,074
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$124,999
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$43,750
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$2,858,772
P30 · FY2014 · CA · contact PI
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$849,999
UM1 · FY2014 · CA · contact PI
Cancer Center Support Grant$213,244
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$115,673
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$75,000
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$2,116,924
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$640,685
P30 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$170,750
U01 · FY2013 · CA · contact PI
Cancer Center Support Grant$124,999
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$111,497
P30 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$81,322
U01 · FY2013 · CA · contact PI
Cancer Center Support Grant$49,999
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$31,250
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$1
P30 · FY2013 · CA · contact PI
Cancer Center Support Grant$3,001,679
P30 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$247,929
U01 · FY2012 · CA · contact PI
Cancer Center Support Grant$139,119
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$100,117
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$74,529
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$50,641
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant$3,303,385
P30 · FY2011 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$247,746
U01 · FY2011 · CA · contact PI
Cancer Center Support Grant$3,159,662
P30 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$255,596
U01 · FY2010 · CA · contact PI
Cancer Center Support Grant$200,000
P30 · FY2010 · CA · contact PI
Cancer Center Support Grant$113,353
P30 · FY2010 · CA · contact PI
Cancer Center Support Grant$3,159,662
P30 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$255,596
U01 · FY2009 · CA · contact PI
Cancer Center Support Grant$145,089
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$132,336
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$112,990
P30 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$99,000
U01 · FY2009 · CA · contact PI
Cancer Center Support Grant$50,000
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant$3,159,662
P30 · FY2008 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)$250,000
U01 · FY2008 · CA · contact PI
Cancer Center Support Grant$132,337
P30 · FY2008 · CA · contact PI
Cancer Center Support Grant$111,931
P30 · FY2008 · CA · contact PI